A partner and Chair of Osler’s National Intellectual Property Department, Brad heads the Firm’s patent litigation and patent/design prosecution practices. Brad has significant expertise in complex patent litigation, including pharmaceutical proceedings under PM(NOC) Regulations. He provides strategic advice on the enforcement of patent rights and coordination and management of litigation strategies throughout multiple jurisdictions.
Brad has appeared as lead counsel before the Federal Court of Appeal, Federal Court, Ontario Superior Court and as worldwide coordinating litigation and IP counsel before the US International Trade Commission. A Registered Patent Agent, Brad specialises in Canadian and foreign patent and industrial design prosecution, strategic IP portfolio reviews, patentability, patent infringement and validity opinions, worldwide patent portfolio management and enforcement advice. He is registered to practise before the USPTO and is a past associate editor of the Canadian Patent Reporter.
Osler’s IP Group was recently recognized as Patent Firm of the Year at the Global IP Awards. Brad personally has been recognized in multiple major legal guides, including most recently honoured as the 2022 Patent Practitioner of the Year (Canada) by Managing Intellectual Property (MIP). Brad’s other recognition includes Chambers Canada: Intellectual Property: Litigation - Band 1, Chambers Global: Intellectual Property Litigation and Intellectual Property, The Canadian Legal Lexpert Directory: Intellectual Property; Biotechnology; Litigation – Intellectual Property, Lexpert Guide to the Leading US/Canada Cross-Border Litigation Lawyers, Best Lawyers in Canada: Intellectual Property Law, Lexpert Special Edition - Litigation: Recognized as a Leader, Who’s Who Legal: Life Sciences - Patent Litigation and Patents (Global Leader); Life Sciences and Patents (National Leader), Thomson Reuters: Stand-out Lawyer, Benchmark Litigation Canada: Intellectual Property; Dispute Resolution (Litigation Star), Intellectual Asset Magazine (IAM) Patent 1000: Recognized as a Global Leader; One of the World’s Leading Patent Litigators and Prosecutors; Intellectual Asset Magazine (IAM) Strategy 300 Global Leaders: One of the World’s Leading IP Strategists, Managing IP: Patent Star, Legal 500: Leading Lawyer, Intellectual Property and LMG Life Sciences: Leading Lawyer (Intellectual Property); World Intellectual Property Review (WIPR): Global Leader (2023).
Representative Work
Mylan Pharmaceuticals ULC:
- Lead outside counsel to Mylan Pharmaceuticals ULC in patent litigation, prosecution and other matters. Presently representing or successfully settled numerous complex pharmaceutical litigation matters on behalf of Mylan in relation to products seeking market entry including TECTA® (Pantoprazole Mg), CIALIS® (Tadalafil), SENSIPAR® (Cinacalcet) and VIMOVO® (Naproxen and esomeprazole Mg).
- Eli Lilly et al. v. Mylan Pharmaceuticals ULC T-1627-16
- Amgen Inc et. al. v BHP Pharma ULC dba Mylan EPD T-420-19
- AstraZeneca Canada Inc. et al. v Mylan Pharmaceuticals ULC et al. T-336-15 (2017), T-184-19
- Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1161-13 (2015) FC 751
- Takeda Pharmaceuticals et al. v. Mylan Pharmaceuticals ULC et al. T-1451-11 (2015)
- Amgen Canada Inc. v Mylan Pharmaceuticals ULC et al. T-2056-14 (2015)
- Amgen Canada Inc. v. Mylan Pharmaceuticals ULC et al T-1584-17
- (Federal Court File No. T-1584-17) SENSIPAR (Cinacalcet) Section 8 Damages
- Novartis Pharmaceuticals v Mylan Pharmaceuticals ULC et al. T-365-14 (2014)
- AstraZeneca et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 312, 2012 FCA 109
- Pfizer Canada Inc et al. v Mylan Pharmaceuticals ULC et al. 2011 FC 547; 2012 FCA 103
- Janssen Inc. v Mylan Pharmaceuticals ULC et al. T-1577-14 (2011)
- Sanofi-Aventis v Mylan Pharmaceuticals ULC et al. T-1441-12 (2010)
- Lundbeck Canada Inc. v Mylan Pharmaceuticals ULC et al. (2009) 73 C.P.R. (4th) 69 (F.C.T.D.); (2010) 88 C.P.R. (4th) 325 (F.C.A.), SCC 34068
Teva Canada Limited:
- Lead outside counsel to Teva Canada Limited in patent litigation, prosecution and other matters. Presently representing or successfully settled complex pharmaceutical and general litigation matters on behalf of Teva including in relation to CUBICIN® (Daptomycin), SPRYCEL® (Dasatinib Monohydrate) and VICTOZA® (Liraglutide).
- Bristol-Myers Squibb Canada Co v. Teva Canada Limited T-1774-18
- Bayer Inc. and Bayer Intellectual Property GMBH v. Teva Canada Limited T-1960-18, T-1021-19.
- Bayer Inc. et al v. Teva Canada Limited T-1692-18
- Novo Nordisk Canada Inc. v. Teva Canada Ltd. et al. T-727-18, T-65-19
Teva/Celltrion Healthcare:
- Lead outside counsel to Teva/Celltrion in complex pharmaceutical litigation matters including the biosimilars to RITUXAN® (Rituximab) and HERCEPTIN® (Trastuzumab).
- F. Hoffmann-La Roche Limited v. Celltrion et al. T-1486-17, T-1487-17, T-1488-17, T-1489-17
- Genentech, Inc. et al. v. Celltrion Healthcare Co., Ltd. T-1969-17, T-1970-17, T-1971-17
Samsung Bioepis:
- Representing Samsung Bioepis in several significant patent litigation cases, including the first case brought in Canada under the Patented Medicines (Notice of Compliance) Regulations in relation to blockbuster biopharmaceutical ENBREL® (etanercept). Also represented Samsung in patent litigation proceedings relation to the world’s biggest drug HUMIRA® (adalimumab).
- Abbvie Biotechnology et al v. Samsung Bioepis Co., Ltd. and the Minister of Health T-598-17, T-599-17, T-600-17, T-601-17, T-602-17, T-603-17, T-604-17, T-605-17
- Amgen Canada Inc. and Immunex Corporation v. Samsung Bioepis Co., Ltd. and the Minister of Health T-1283-15 (2014)
Standard Innovation Corporation:
- Representing Standard Innovation Corporation (now WOW Tech) in the role of world-wide coordinating litigation and IP counsel, including the following cases:
- Opposition Proceedings in respect of European Patent No. EP 1 824 440 in the European Patent Office
- Appeal from the US International Trade Commission, Investigation No. 337-TA-823, United States Court of Appeals for the Federal Circuit, No. 2013-1582, Lelo Inc. & Leloi AB v. International Trade Commission and Standard Innovation (US) Corp. & Standard Innovation Corporation
- District Court Action before the United States District Court of Northern California 5:13-cv-01393-PSG: Lelo Inc v. Standard Innovation (US) Corp and Standard Innovation Corporation
- Ex Parte reexamination of the United States Patent No. 7,931,605 (“the ‘605 Patent”)
- Lead Canadian IP counsel to Standard Innovation Corporation including in T-925-12: Standard Innovation Corporation v. Lelo AB et Lelo Inc., 1531011 Ontario Inc., Cana International Distributing Inc., Landco Import International Inc. and TBMBM Inc.
- Two Inter Partes Review Re: Standard Innovation Corporation (Petitioner) v. Lelo Inc. [Patent Owner; Cases IPR 2014-00148 and IPR 2014-00907, Re: United States Patent No. 7,749,178 (“the ‘178 Patent”)].
ratiopharm Inc:
- Abbott Laboratories v. ratiopharm Inc. et al. (2004), 31 C.P.R. (4th) 321 (F.C.A.)
- Abbott Laboratories v. ratiopharm Inc. et al. (2005), 42 C.P.R. (4th) 20 and 121 (F.C.T.D.)
- Abbott Laboratories v. ratiopharm Inc. et al. (2005) 34 C.P.R. (4th) 468 (F.C.T.D.)
Novopharm Ltd:
- Janssen-Ortho Inc. and Daiichi Pharmaceutical Co, Ltd. v. Novopharm Ltd. et al. 2006 FC 1333, (2006) 57 C.P.R. (4th) 6 and 58 (F.C.T.D.)
- Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 39 C.P.R. (4th) 197 (F.C.A.)
- Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 35 C.P.R (4th) 353 (F.C.T.D.), appeal dismissed (2005), 40 C.P.R. (4TH) 1 (F.C.A.)
Other:
- Acting as counsel to Munchkin Baby Canada, Ltd. and its U.S. affiliate in the defence of a Federal Court patent infringement action relating to the defendants’ making and selling of cartridges for diaper pails. Angelcare Development Inc. et al. v. Munchkin, Inc et al T-151-16
- Counsel to Skretting Canada Inc. in letters rogatory proceedings relating a US patent dispute concerning methods for raising fish. Marical, Inc. v. Skretting Canada Inc. SJM-51-2016
- Nycomed v. Genpharm ULC et al. 2008 FC 330, (2008), 64 C.P.R. (4th) 388 (F.C.T.D.)
Latest Insights
-
Report Dec 5, 2024
The impact of stronger drug dosing patents on Canadian drug access
A consistent pain point and focus of reform within the system is the high cost of prescription drugs.
Read more -
Osler Update Jul 22, 2024
U.K. appellate court rules artificial neural network application is not patent-eligible subject matter
Although artificial neural networks (ANNs) have evolved to increasingly form the backbone of modern commerce, their patentability remained...
Read more -
Osler Update Dec 1, 2023
Canadian Intellectual Property Office (CIPO) increasing official fees effective January 1, 2024
CIPO is set to substantially increase official fees for patents, trademarks, industrial designs and copyrights on January 1, 2024.
Read more -
Osler Update Jun 22, 2022
Canadian Court again rejects problem-solution approach to subject-matter eligibility of computer-implemented patents
The Federal Court of Canada has once again rejected the problem-solution approach to determining eligibility for computer-implemented patent...
Read more
Awards and Recognition
-
Managing Intellectual Property Americas Awards 2022: Practitioner of the Year – Patent (Canada)
-
Chambers Canada: Recognized in Intellectual Property: Litigation (Band 1)
-
Chambers Global: Recognized in Intellectual Property: Litigation (Band 1)
-
The Canadian Legal Lexpert Directory: Intellectual Property; Life Sciences & Health; Litigation – Intellectual Property
-
Lexpert Special Edition – Litigation: Recognized as a Leader
-
Lexpert Special Edition: Recognized in Technology and Health Sciences; Recognized in Litigation
-
Best Lawyers: Intellectual Property Law (Canada)
-
Who’s Who Legal: Life Sciences – Patent Litigation and Patents (Global Leader); Life Sciences and Patents (National Leader)
-
Thomson Reuters: “Stand-out Lawyer”
-
Benchmark Litigation Canada: Intellectual Property; Dispute Resolution (Litigation Star)
-
Intellectual Asset Magazine (IAM) Patent 1000: Recognized as a Global Leader; One of the World’s Leading Patent Litigators and Prosecutors, Individuals: Litigation (Gold), Individuals: Prosecution (Recommended); Intellectual Asset Magazine (IAM) Strategy 300 Global Leaders: One of the World’s Leading IP Strategists
-
Managing IP: IP Star, Patent, Copyright (Canada)
-
Legal 500: Leading Lawyer, Intellectual Property
-
LMG Life Sciences: Leading Lawyer (Intellectual Property)
-
World Intellectual Property Review (WIPR): Global Leader (2023)
Media Mentions
-
Osler News Nov 15, 2024
Leading patent lawyer recognition for Bradley White
Bradley White, partner and Chair of Osler’s Intellectual Property practice, has been named by IAM Global Leaders 2025 as a leading patent lawyer...
Read more -
Osler News Aug 16, 2024
Brad White named in IAM Strategy 300: The World’s Leading IP Strategists for 2024
Osler is pleased to announce that Brad White has been named in IAM Strategy 300: The World’s Leading IP Strategists for 2024. IAM Strategy 300...
Read more -
Osler News Apr 22, 2024
Six Osler lawyers recognized by Who’s Who Legal Life Sciences — Canada
Osler congratulations the six members of the firm who have earned the “Recommended” rating from Who’s Who Legal (WWL) Life Sciences — Canada.
Read more -
Osler News Feb 16, 2024
Osler recognized as a leading firm in Chambers Global 2024 Guide
Osler recognized as a leading firm in Chambers Global 2024 Guide
Read more
Community Involvement
- Royal Ottawa Golf Club, Past Board Member (3 years service)
Speaking and Writing
Published Work
Scientific Publications
- Co-author of the Canadian Intellectual Property Guide 2018 published by the Chinese National Intellectual Property Administration (CNIPA – formerly SIPO).
- J.B.White, M.Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of InH and InD, J. Mol. Spec., 169, 410-420 (1995).
- T. Karkanis, Z. Morbi, J.B. White, M. Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectrum of InF, Canadian J. Phys., 72, 1213-1217 (1994).
- R. LeBlanc, J.B. White and P,F. Bernath, Improved Rotational Constants far HCI and HF, J, Mol, Spec., 164, 574 (1994).
- J.B. White, M,Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of AIH and AID J. Chem. Phys., 99, 8371 (Dec. 1993).
- J.Campbell, M.Dulick, D.Klapstein, J.B. White and P.F.Bernath, The High Resolution Infrared Emission Spectra of GaH and GaD, J Chem. Phys., 99, 8379 (Dec. 1993).
- Key issues for senior life sciences executives, IP in the Life Sciences Industries 2014 (This article first appeared in Intellectual Asset Management issue 66, published by The IP Media Group. To view the report in full, go to www.iam-magazine.com)
Other Publications
Credentials
Education
- University of Windsor, LL.B.
- University of Waterloo, M.Sc.
- University of Western Ontario, B.Sc.
Languages
- English
Professional Affiliations
- Intellectual Property Institute of Canada
- American Intellectual Property Law Association
- International Association for the Protection of Intellectual Property (AIPPI)
- Canadian Bar Association